ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells

Cancer Medicine

Volumn 1, Issue 1, 2012, Pages 28-38

  Choi, Byung Kwon ^a   Fan, Xuejun ^a   Deng, Hui ^a   Zhang, Ningyan ^a   An, Zhiqiang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Anti HER2 antibody; EGFR; ERBB2 HER2; ERBB3 HER3; MCF7; Signaling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HER2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DIMERIZATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 84880694158     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.10     Document Type: Article

References (44)

1. Lemmon, M. A., and J. Schlessinger. 2010. Cell signaling by receptor tyrosine kinases. Cell 141:1117-1134.
2. Hynes, N. E., and H. A. Lane. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5:341-354.
3. Schoeberl, B., E. A. Pace, J. B. Fitzgerald, B. D. Harms, L. Xu, and L. Nie, et al. 2009. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal 2:ra31.
4. Junttila, T. T., R. W. Akita, K. Parsons, C. Fields, G. D. Lewis Phillips, and L. S. Friedman, et al. 2009. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440.
5. Baselga, J., and S. M. Swain. 2009. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9:463-475.
6. Jain, A., E. Penuel, S. Mink, J. Schmidt, A. Hodge, and K. Favero, et al. 2010. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 70:1989-1999.
7. Adams, C. W., D. E. Allison, K. Flagella, L. Presta, J. Clarke, and N. Dybdal, et al. 2006. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol. Immunother. 55:717-727.
8. Cai, Z., G. Zhang, Z. Zhou, K. Bembas, J. A. Drebin, and M. I. Greene, et al. 2008. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene 27:3870-3874.
9. Sonne-Hansen, K., I. C. Norrie, K. B. Emdal, R. V. Benjaminsen, T. Frogne, and I. J. Christiansen, et al. 2010. Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Res. Treat. 121:601-613.
10. Glantschnig, H., K. Scott, R. Hampton, N. Wei, P. McCracken, and P. Nantermet, et al. 2011. A rate-limiting role for dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J. Pharmacol. Exp. Ther. 338:568-578.
11. Soderberg, O., M. Gullberg, M. Jarvius, K. Ridderstrale, K. J. Leuchowius, and J. Jarvius, et al. 2006. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3:995-1000.
12. Fan, A. C., D. Deb-Basu, M. W. Orban, J. R. Gotlib, Y. Natkunam, and R. O'Neill, et al. 2009. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat. Med. 15:566-571.
13. Rosen, L. S., H. L. Ashurst, and L. Chap. 2010. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 15:216-235.
14. Sierke, S. L., K. Cheng, H. H. Kim, and J. G. Koland. 1997. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem. J. 322(Pt 3):757-763.
15. Berger, M. B., J. M. Mendrola, and M. A. Lemmon. 2004. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett. 569:332-336.
16. Reschke, M., D. Mihic-Probst, E. H. van der Horst, P. Knyazev, P. J. Wild, and M. Hutterer, et al. 2008. HER3 is a determinant for poor prognosis in melanoma. Clin. Cancer Res. 14:5188-5197.
17. Frolov, A., K. Schuller, C. W. Tzeng, E. E. Cannon, B. C. Ku, and J. H. Howard, et al. 2007. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol. Ther. 6:548-554.
18. van der Horst, E. H., M. Murgia, M. Treder, and A. Ullrich. 2005. Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. Int. J. Cancer 115:519-527.
19. Jiang, X., R. A. Borgesi, N. C. McKnight, R. Kaur, C. L. Carpenter, and S. P. Balk. 2007. Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J. Biol. Chem. 282:32689-32698.
20. Nagumo, Y., D. Faratian, P. Mullen, D. J. Harrison, M. Hasmann, and S. P. Langdon. 2009. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Mol. Cancer Res. 7:1563-1571.
21. Yoon, Y. K., H. P. Kim, S. W. Han, H. S. Hur, do. Y. Oh, and S. A. Im, et al. 2009. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol. Cancer Ther. 8:2526-2536.
22. Suenaga, A., N. Takada, M. Hatakeyama, M. Ichikawa, X. Yu, and K. Tomii, et al. 2005. Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides. J. Biol. Chem. 280:1321-1326.
23. Mattoon, D. R., B. Lamothe, I. Lax, and J. Schlessinger. 2004. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol. 2:24.
24. Amin, D. N., N. Sergina, D. Ahuja, M. McMahon, J. A. Blair, and D. Wang, et al. 2010. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med. 2:16ra7.
25. Chakrabarty, A., V. Sanchez, M. G. Kuba, C. Rinehart, and C. L. Arteaga. 2011. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl Acad. Sci. USA 109:2718-2723.
26. Da Silva, L., P. T. Simpson, C. E. Smart, S. Cocciardi, N. Waddell, and A. Lane, et al. 2010. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res. 12:R46.
27. Garrett, J. T., M. G. Olivares, C. Rinehart, N. D. Granja-Ingram, V. Sanchez, and A. Chakrabarty, et al. 2011. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl Acad. Sci. USA 108:5021-5026.
28. Smirnova, T., Z. N. Zhou, R. J. Flinn, J. Wyckoff, P. J. Boimel, and M. Pozzuto, et al. 2011. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene 31:706-715.
29. Wilson, T. R., D. Y. Lee, L. Berry, D. S. Shames, and J. Settleman. 2011. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 20:158-172.
30. Engelman, J. A., K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, and J. O. Park, et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043.
31. Sergina, N. V., M. Rausch, D. Wang, J. Blair, B. Hann, and K. M. Shokat, et al. 2007. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441.
32. Narayan, M., J. A. Wilken, L. N. Harris, A. T. Baron, K. D. Kimbler, and N. J. Maihle. 2009. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res. 69:2191-2194.
33. Lee-Hoeflich, S. T., L. Crocker, E. Yao, T. Pham, X. Munroe, and K. P. Hoeflich, et al. 2008. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68:5878-5887.
34. Dunn, M., P. Sinha, R. Campbell, E. Blackburn, N. Levinson, and R. Rampaul, et al. 2004. Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. J. Pathol. 203:672-680.
35. Takai, N., A. Jain, N. Kawamata, L. M. Popoviciu, J. W. Said, and S. Whittaker, et al. 2005. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104:2701-2708.
36. Arpino, G., C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, and L. Bharwani, et al. 2007. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J. Natl Cancer Inst. 99: 694-705.
37. Jackson, J. G., P. St Clair, M. X. Sliwkowski, and M. G. Brattain. 2004. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res. 64:2601-2609.
38. Osipo, C., K. Meeke, D. Cheng, A. Weichel, A. Bertucci, and H. Liu, et al. 2007. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Int. J. Oncol. 30:509-520.
39. Agus, D. B., R. W. Akita, W. D. Fox, G. D. Lewis, B. Higgins, and P. I. Pisacane, et al. 2002. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137.
40. Chung, I., R. Akita, R. Vandlen, D. Toomre, J. Schlessinger, and I. Mellman. 2010. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 464:783-787.
41. Brockhoff, G., B. Heckel, E. Schmidt-Bruecken, M. Plander, F. Hofstaedter, and A. Vollmann, et al. 2007. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif. 40:488-507.
42. Baselga, J., K. A. Gelmon, S. Verma, A. Wardley, P. Conte, and D. Miles, et al. 2010. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28:1138-1144.
43. Gianni, L., A. Llado, G. Bianchi, J. Cortes, P. L. Kellokumpu-Lehtinen, and D. A. Cameron, et al. 2010. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28:1131-1137.
44. Mittendorf, E. A., Y. Wu, M. Scaltriti, F. Meric-Bernstam, K. K. Hunt, and S. Dawood, et al. 2009. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin. Cancer Res. 15:7381-7388.